Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting.

PLoS One · 2021 · PMC8360580 · PMID 34383787

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not achieve significanceno p-value reported

Numerically, CD3, CD8 and FoxP3 TILs increased over the course of the treatment and was maximal at 13 days; however, these changes did not achieve significance ( Fig 9 ).

also in 1,397 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.